Skip to main content

imgn151

Generic: Opugotamig Olatansine·Code: IMGN151

imgn151: 2 clinical trials tracked.

imgn151 evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about imgn151, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (2)

A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers

NCT07024784·Phase 2·ABBV
Recruiting

Primary endpoint: Number of Participants With Dose-limiting Toxicities (DLTs)

InterventionalRandomizedopen377 targetStarted 2025-07Completion 2028-0216 sites · Israel, Japan, United StatesAbbVie

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers

NCT05527184·Phase 1·ABBV
Active, not recruiting

Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen256 targetStarted 2023-01Completion 2027-0250 sites · Australia, Belgium, Canada, France…AbbVie